146 related articles for article (PubMed ID: 31568820)
1. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
2. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.
Becciolini A; Raimondo MG; Crotti C; Agape E; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():1969-1978. PubMed ID: 28721016
[TBL] [Abstract][Full Text] [Related]
3. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Uhlig T; Goll GL
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
6. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.
Moots R; Azevedo V; Coindreau JL; Dörner T; Mahgoub E; Mysler E; Scheinberg M; Marshall L
Curr Rheumatol Rep; 2017 Jun; 19(6):37. PubMed ID: 28623625
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
Jacobs I; Petersel D; Isakov L; Lula S; Lea Sewell K
BioDrugs; 2016 Dec; 30(6):525-570. PubMed ID: 27885553
[TBL] [Abstract][Full Text] [Related]
8. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
[No Abstract] [Full Text] [Related]
9. Potential for biosimilars in rheumatology in Africa.
Abu-Zaid MH; Adebajo A; El Miedany Y
Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
[TBL] [Abstract][Full Text] [Related]
10. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
11. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
12. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway.
Goll GL; Kvien TK
Expert Opin Biol Ther; 2023; 23(12):1203-1209. PubMed ID: 37874218
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.
Jacobs I; Petersel D; Shane LG; Ng CK; Kirchhoff C; Finch G; Lula S
BioDrugs; 2016 Dec; 30(6):489-523. PubMed ID: 27807766
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic antibodies in rheumatology].
Albach FN; Burmester GR; Mucke J
Z Rheumatol; 2024 Mar; 83(2):98-104. PubMed ID: 37656186
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics.
Steedman S; Giang J
J Manag Care Spec Pharm; 2024 Jan; 30(1):22-25. PubMed ID: 38153865
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in childhood chronic rheumatic diseases: friend or foe?
Maccora I; Simonini G
Lancet Rheumatol; 2024 Jul; 6(7):e413-e414. PubMed ID: 38843857
[No Abstract] [Full Text] [Related]
17. An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar.
Fusaro E; Durez P; Wohlrab J; Lee S; SangWook Yoon ; Marotte H
Immunotherapy; 2021 Dec; ():. PubMed ID: 34865524
[TBL] [Abstract][Full Text] [Related]
18. [PHARAO study: drug treatment of inflammatory rheumatic diseases : Guideline-conform treatment with biologics follows availability of biosimilars].
Hörbrand F; Schuch F; Bleß HH; Messinger D; Bretthauer B; Killian P
Z Rheumatol; 2023 Nov; 82(9):787-797. PubMed ID: 36006471
[TBL] [Abstract][Full Text] [Related]
19. Bridging the gap: The future of biosimilars regulations.
Jarab AS; Abu Heshmeh SR; Al Meslamani AZ
Hum Vaccin Immunother; 2024 Dec; 20(1):2362450. PubMed ID: 38887055
[TBL] [Abstract][Full Text] [Related]
20. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
Kay J; Schoels MM; Dörner T; Emery P; Kvien TK; Smolen JS; Breedveld FC;
Ann Rheum Dis; 2018 Feb; 77(2):165-174. PubMed ID: 28866648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
